All News

Gladman et al. PsA patients treated with guselkumab in DISCOVER-2. Male patients had more radiographic progression. Males exhibit stronger relationship between early joint response and lower subsequent rates radiographic progression. @RheumNow #ACR25 Abstr#2345 https://t.co/TSNwesvPzj

https://x.com/RichardPAConway/status/1983209393073336544/photo/1

Mulcaire-Jones et al. Changes in PFTs over 1 year in early RA. Improved 31%, worsened 25%. No difference based on baseline disease activity, or MTX use. Those with baseline ILD were MORE likely to improve. ?due to effect of treatment @RheumNow #ACR25 Abstr#2235 https://t.co/bJeLYN9oN7

https://x.com/RichardPAConway/status/1983209141708452314/photo/1

EGPA relapse in MANDARA including OLE Majority of relapses are asthma / sinonasal in nature Of non-airway: - arthralgia/myalgia - sensory peripheral neuropathy @RheumNow #ACR25 Abst1769 https://t.co/cPjjzl4RWS

CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

https://x.com/AkhilSoodMD/status/1983207128077873559/photo/1

Punjadath et al. Predictors of progression palindromic rheumatism to RA. 30 patients. 47% progressed to RA. Total number of joints involved, RF, CRP predicted progression univariate. Only total joints significant in mutlivariate but underpowered. @RheumNow #ACR25 Abstr#2261 https://t.co/FtVKdGtEr9

https://x.com/RichardPAConway/status/1983206625205793213/photo/1

Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi

https://x.com/EBRheum/status/1983206373065470152/photo/1

Can fiber make methotrexate work better? (LB15) In a placebo-controlled Superfibers RCT, inulin 12 g/day improved EULAR response & Th17/Treg ratio in RA among MTX users. @RheumNow #ACR25 https://t.co/awMRNloNw5

https://x.com/JihaRheum/status/1983206122069643401/photo/1

Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy RCT of 119 pt 57.1% response at wk 28 in SEC 27% response at wk 28 in UST Numerically lower adverse events leading to d/c in SEC @RheumNow #ACR25 #ACRBest Abst LB06 https://t.co/wDxtscP2ku

https://x.com/Dr_Brian_MD/status/1983206111298650538/photo/1

Does fiber boost MTX efficacy? LB15: Fiber + MTX led to 📉 Greater drop in DAS28 (–1.00 vs –0.34 placebo) 🧬 ↓ Th17 cells & Th17/Treg ratio Some food for thought @RheumNow #ACR25 https://t.co/VhLVP1nRy2

https://x.com/AkhilSoodMD/status/1983205870218760461/photo/1

Serrano-Combarro et al. Baricitinib in RA-ILD. Observational, 42 patients. Progressive ILD in 26%. More frequent in women. @RheumNow #ACR25 Abstr#2229 https://t.co/ZXfgxKoau7

https://x.com/RichardPAConway/status/1983205618925129939/photo/1

Benson et al. Clinical features that predict CV risk in PsA. Median 3.53 year follow up. 56 CV events. 766 patients. Dactylitis emerged as key predictor in adjusted models. @RheumNow #ACR25 Abstr#2317 https://t.co/5O3G7vGYbq

https://x.com/RichardPAConway/status/1983205114946183664/photo/1

Cutaneous vasculitis: who is most likely to have systemic disease? 430 pt w skin vasculitis examined in case-control Associated with risk for systemic vasculitis/CTD: - GI sx - ulcerating/necrotic lesions - constitutional sx - hematuria @RheumNow #ACR25 Abst 2525 https://t.co/lRjLKRYxDW

https://x.com/Dr_Brian_MD/status/1983204033729892687/photo/1

How great would it be to have a diagnostic RA-ILD Urine Dipstick? Small cohort 14 RA-ILD vs. 64 RA no ILD Urine ILDScore includes 2 proteins SPOCK1 and PGRMC1 Independently asso with ILD w/ OR 6.19 Urine ILD score alone AUC 0.9 ILD urine score + clinical data AUC = 0.95 Needs https://t.co/7PqX8kdjKJ

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

https://x.com/AkhilSoodMD/status/1983203353975808401/photo/1

Interesting study evaluating the "CALLY" index (serum albumin × lymphocyte count / CRP / 10,000) for predicing mortality in AAV I typically dislike these because (1) they are often cumbersome to calculate & (2) they often perform poorly This one piqued my interest; pretty https://t.co/ziroQOH5Cq

https://x.com/EBRheum/status/1983203214729085107/photo/1

Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb

https://x.com/synovialjoints/status/1983202097903370743/photo/1

IgG4-RD continues to present in new and unusual ways Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement RCA and LAD most affected Seen on CTA Majority received RTX 7/9 pt at least partially improved imaging on f/u @RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb

https://x.com/Dr_Brian_MD/status/1983201652707602640/photo/1

A new genetic score for ILD prediction! 🫁 Developed in the Veterans RA cohort and Validation in a Swedish cohort Model using classic RA-ILD risk factors and a cocktail of genetic risk A cut off of 0.05 in this cohort would exclude 36% from HRCT or PFTs Good performance https://t.co/6UsoSQAtyK

RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck) Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪 @RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k

Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32

https://x.com/RichardPAConway/status/1983201088410136955/photo/1

Topics

All News

Do you get our email newsletter?